Efficacy of Saxagliptin for Blood Glucose Control in Hemodialysis Patients with Diabetes

• Published in: YAKUGAKU ZASSHI Vol. 140; no. 7; pp. 937 - 941
• Main Authors: Sakurai, Junji, Satoh, Shinsuke, Hase, Miori, Takahashi, Tomoko, Ojima, Fumiyoshi, Andou, Shigeki, Kishikawa, Yukinaga, Ishizawa, Fumiaki, Satoh, Jo
• Format: Journal Article
• Language: Japanese
• Published: The Pharmaceutical Society of Japan 01.07.2020
• Subjects: glycated albumin; hemodialysis; saxagliptin
• ISSN: 0031-6903; 1347-5231
• DOI: 10.1248/yakushi.19-00249

Studies on the drug saxagliptin (marketed in Japan since 2013) suggest favorable efficacy in hemodialysis patients, but included small sample sizes. Noting that some hemodialysis patients at our medical institution had been switched to saxagliptin 2.5 mg from treatment with other dipeptidyl peptidase-4 inhibitors, we decided to evaluate the effects of switching to saxagliptin on blood glucose control in these patients. The study included 11 patients. Before switching drugs, six of the patients used teneligliptin 20 mg and five used linagliptin 5 mg. Mean glycated albumin (GA) from before to 4 months after switching tended to increase in the previous users of teneligliptin 20 mg (18.4±3.0% to 19.5±2.7%) and tended to decrease in the previous users of linagliptin 5 mg (18.8±3.3% to 17.7±1.4%). Lack of a substantial change in GA when the previous users of teneligliptin 20 mg and linagliptin 5 mg were switched to saxagliptin 2.5 mg indicates that these three agents might have comparable antihyperglycemic profiles when used in patients on hemodialysis. Future research following from this pilot study must evaluate the risk of cardiac failure and incidences of adverse events in a larger population, to investigate the long-term efficacy and safety of switching to saxagliptin.